Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may
stimulate the immune system to help fight cancer. The purpose of the study is to assess the
safety of the investigational drug and to identify the highest dose that is well-tolerated.
The pharmacology of VTX-2337 will also be evaluated.